Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
antibody - function
blood safety
pathogen inactivation
plasma
transfusion therapy
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
11
03
2021
received:
09
02
2021
accepted:
11
03
2021
pubmed:
10
4
2021
medline:
16
11
2021
entrez:
9
4
2021
Statut:
ppublish
Résumé
Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID-19), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not transmissible by transfusion, but bloodborne pathogens remain a risk in regions with high endemic prevalence of disease. Pathogen reduction can mitigate this risk; thus, the objective of this study was to evaluate the effect of riboflavin and ultraviolet light (R + UV) pathogen reduction technology on the functional properties of COVID-19 CP (CCP). COVID-19 convalescent plasma units (n = 6) from recovered COVID-19 research donors were treated with R + UV. Pre- and post-treatment samples were tested for coagulation factor and immunoglobulin retention. Antibody binding to spike protein receptor-binding domain (RBD), S1 and S2 epitopes of SARS-CoV-2 was assessed by ELISA. Neutralizing antibody (nAb) function was assessed by pseudovirus reporter viral particle neutralization (RVPN) assay and plaque reduction neutralization test (PRNT). Mean retention of coagulation factors was ≥70%, while retention of immunoglobulins was 100%. Starting nAb titres were low, but PRNT R + UV PRT effects on coagulation factors were similar to previous reports, but no significant effects were observed on immunoglobulin concentration and antibody function. SARS-CoV-2 nAb function in CCP is conserved following R + UV PRT treatment.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID-19), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not transmissible by transfusion, but bloodborne pathogens remain a risk in regions with high endemic prevalence of disease. Pathogen reduction can mitigate this risk; thus, the objective of this study was to evaluate the effect of riboflavin and ultraviolet light (R + UV) pathogen reduction technology on the functional properties of COVID-19 CP (CCP).
MATERIALS AND METHODS
METHODS
COVID-19 convalescent plasma units (n = 6) from recovered COVID-19 research donors were treated with R + UV. Pre- and post-treatment samples were tested for coagulation factor and immunoglobulin retention. Antibody binding to spike protein receptor-binding domain (RBD), S1 and S2 epitopes of SARS-CoV-2 was assessed by ELISA. Neutralizing antibody (nAb) function was assessed by pseudovirus reporter viral particle neutralization (RVPN) assay and plaque reduction neutralization test (PRNT).
RESULTS
RESULTS
Mean retention of coagulation factors was ≥70%, while retention of immunoglobulins was 100%. Starting nAb titres were low, but PRNT
CONCLUSION
CONCLUSIONS
R + UV PRT effects on coagulation factors were similar to previous reports, but no significant effects were observed on immunoglobulin concentration and antibody function. SARS-CoV-2 nAb function in CCP is conserved following R + UV PRT treatment.
Identifiants
pubmed: 33835489
doi: 10.1111/vox.13108
pmc: PMC8251479
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Riboflavin
TLM2976OFR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1076-1083Subventions
Organisme : Terumo BCT
Informations de copyright
© 2021 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Références
Transfusion. 2013 Jan;53 Suppl 1:137S-149S
pubmed: 23301966
Transfusion. 2019 Sep;59(9):3002-3025
pubmed: 31144334
Vox Sang. 2010 Feb;98(2):108-15
pubmed: 19719460
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
Am J Trop Med Hyg. 2016 Sep 7;95(3):647-653
pubmed: 27430546
Vox Sang. 2009 Apr;96(3):213-8
pubmed: 19207170
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
Vox Sang. 2018 Oct;113(7):622-631
pubmed: 30079963
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Transfus Apher Sci. 2011 Feb;44(1):25-31
pubmed: 21251884
Vox Sang. 2020 Aug;115(6):495-501
pubmed: 32311760
Vox Sang. 2020 Aug;115(6):485-487
pubmed: 32319102
PLoS One. 2020 May 29;15(5):e0233947
pubmed: 32470046
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Transfusion. 2020 May;60(5):1024-1031
pubmed: 32129478
Clin Infect Dis. 2016 Jan 1;62(1):69-74
pubmed: 26261205
Transfusion. 2013 Jan;53 Suppl 1:131S-136S
pubmed: 23301965
Transfusion. 2016 Mar;56 Suppl 1:S6-15
pubmed: 27001363
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
J Antimicrob Chemother. 2005 Nov;56(5):919-22
pubmed: 16183666
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Ann Intern Med. 2006 Oct 17;145(8):599-609
pubmed: 16940336
Transfusion. 2021 Apr;61(4):1160-1170
pubmed: 33554362
J Infect. 2017 Mar;74(3):302-309
pubmed: 27867062
Hong Kong Med J. 2003 Jun;9(3):199-201
pubmed: 12777656
Transfus Apher Sci. 2015 Feb;52(1):19-34
pubmed: 25620756
Transfus Apher Sci. 2009 Dec;41(3):199-204
pubmed: 19782644
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Transfusion. 2009 Oct;49(10):2167-72
pubmed: 19555414
Transfusion. 2010 Apr;50(4):926-31
pubmed: 20051060
Transfusion. 2003 Sep;43(9):1322-9
pubmed: 12919437
Photochem Photobiol. 2014 Sep-Oct;90(5):957-64
pubmed: 25041351
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
N Engl J Med. 2016 Dec 8;375(23):2307-2309
pubmed: 27959686
Curr Opin Hematol. 2004 Sep;11(5):346-50
pubmed: 15666659